$CATX

Biotech firms advance treatment-resistant cancer therapies across multiple platforms, including oncolytic viruses and cellular immunotherapy, with several candidates achieving regulatory milestones and encouraging clinical data.

Perspective Therapeutics will release 2025 financial results and clinical pipeline updates on March 16, highlighting progress in its cancer-targeting radiopharmaceutical programs.